

Amendments to the Claims:

Please cancel claims 46 and 81, add new claims 82 and 83, and amend claims 47-50 and 55-56 as indicated.

Claims 1-45 (Canceled).

46. (Canceled herein).

47. (Currently Amended) The complex of claim ~~46~~ 82 wherein the MHC class II molecules have the subtype DR B1 301 or DR B1 0401.

48. (Currently Amended) The complex of claim ~~46~~ 82, wherein the MHC class II molecules are recombinant MHC class II molecules.

49. (Currently Amended) The complex of claim ~~46~~ 82 wherein the peptide or peptide derivative is bound to a soluble peptide binding derivative of said MHC class II DR3 or DR4 molecules.

50. (Currently Amended) The complex of claim ~~46~~ 82, wherein the complex carries a marker group.

Claims 51-54 (canceled).

55. (Currently Amended) The complex of claim ~~46~~ 82, wherein the peptide or peptide derivative carries a marker group.

56. (Currently Amended) A pharmaceutical composition, comprising a complex as claimed in claim ~~46~~ 82, in combination with a pharmaceutically acceptable carrier.

57. (Previously presented) The pharmaceutical composition of claim 56, further comprising an accessory stimulating component.

58. (Previously presented) The pharmaceutical composition of claim 57, wherein the accessory stimulating component is a cytokine, surface antigen B7, or both.

Claims 59-80 (Canceled).

81. (Canceled herein).

82. (New) An isolated complex comprising a peptide or peptide derivative of glutamic acid decarboxylase which is bound to an allele or a peptide-binding derivative of MHC class II molecules DR3 or DR4 selected from the group consisting of DR B1 0301, DR B1 0401, DR B1 0402 and DR B1 0404,

wherein said peptide is selected from the group consisting of SEQ ID NO:2, 3, 19-39 and a fragment thereof, and wherein said fragment has at least 6 contiguous amino acids of SEQ ID NO:2, 3 or 19-39.

83. (New) An isolated complex comprising a peptide or peptide derivative of glutamic acid decarboxylase which is bound to an allele or a peptide-binding derivative of MHC class II molecules DR3 or DR4 selected from the group consisting of DR B1 0301, DR B1 0401, DR B1 0402 and DR B1 0404,

wherein said peptide is at least 12 contiguous amino acids of SEQ ID NO:2, 3 or 19-39.